| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.60B | 361.39B | 331.13B | 332.59B | 303.92B | 338.57B |
| Gross Profit | 128.29B | 127.56B | 127.67B | 123.85B | 110.75B | 158.03B |
| EBITDA | 29.86B | 28.28B | 29.06B | 34.05B | 27.93B | 35.09B |
| Net Income | 8.19B | 5.04B | 8.11B | 14.13B | 8.10B | 13.52B |
Balance Sheet | ||||||
| Total Assets | 369.01B | 394.13B | 377.77B | 395.74B | 369.05B | 356.74B |
| Cash, Cash Equivalents and Short-Term Investments | 51.84B | 68.63B | 60.24B | 97.20B | 91.93B | 102.25B |
| Total Debt | 7.16B | 154.00M | 165.00M | 30.00B | 30.02B | 30.35B |
| Total Liabilities | 102.36B | 115.59B | 105.18B | 132.63B | 124.30B | 115.57B |
| Stockholders Equity | 266.05B | 277.90B | 272.00B | 262.54B | 244.29B | 240.79B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 19.26B | -15.66B | 9.69B | -8.89B | 4.89B |
| Operating Cash Flow | 0.00 | 29.39B | 1.81B | 28.06B | 16.80B | 28.65B |
| Investing Cash Flow | 0.00 | -16.08B | -10.26B | -8.61B | -20.14B | -29.19B |
| Financing Cash Flow | 0.00 | -6.92B | -39.15B | -6.18B | -10.28B | -4.86B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥485.53B | 16.87 | 10.81% | 2.56% | 3.87% | 29.64% | |
66 Neutral | ¥398.86B | 23.84 | 8.27% | 1.95% | 5.82% | -13.40% | |
65 Neutral | ¥395.13B | 76.68 | 2.66% | 1.64% | 8.40% | -23.50% | |
64 Neutral | ¥339.28B | 21.60 | ― | 2.61% | 6.54% | 15.08% | |
63 Neutral | ¥247.07B | 17.96 | ― | 2.11% | 3.69% | -50.13% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | ¥436.07B | 31.87 | ― | 2.42% | 2.33% | -8.76% |
Ezaki Glico has disclosed that it received a shareholder proposal from LONGCHAMP SICAV, represented by Dalton Investments, seeking to nominate two outside directors, authorize large-scale share buybacks, revise restricted stock compensation, and amend the articles of incorporation to reinforce management awareness of capital costs and share price. After review by its board and its majority-outside Nomination and Compensation Committee, Glico’s directors resolved to oppose the director nominations, arguing the current board already has appropriate skill balance and diversity to execute its long-term strategy and mid-term management plan.
The board also expressed concern that the proposing shareholder is prioritizing short-term share-price gains and a potential take-private transaction, including a management buyout structure involving a private equity fund and rollover investment, which Glico believes could create conflicts of interest with general shareholders. Citing past interactions and public comments by Dalton’s chief investment officer about aiming to take Glico private, the company warned that the proposal could steer it toward privatization on terms misaligned with its focus on medium- to long-term value creation and the common interests of all shareholders.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen6199.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.
Ezaki Glico has authorized a substantial share buyback of up to 4.6 million common shares, representing 7.23% of its outstanding stock excluding treasury shares, with a maximum outlay of ¥25 billion. The purchases will be executed on the Tokyo Stock Exchange between March 1 and December 30, 2026, and all acquired shares are scheduled to be cancelled, signaling a commitment to shareholder returns and balance-sheet optimization.
Management said the move is intended to enhance shareholder returns and provide flexibility in capital policy amid a changing operating environment, with part of the funding to come from borrowings. Given existing treasury stock of about 4.8 million shares at the end of 2025, the additional buyback and planned cancellation are likely to tighten the share float and may support per-share metrics, potentially improving the company’s market valuation and capital efficiency.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen6199.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.
Ezaki Glico announced it has recorded a fixed asset impairment loss related to facilities used in its powdered baby milk business, a part of its Dairy Business. After reassessing the future recoverability of these assets under Japan’s impairment accounting standards, the company wrote down their book value to recoverable levels, resulting in an extraordinary loss of ¥3,393 million in its fiscal year ended December 31, 2025.
The impairment reflects management’s assessment of the business environment and future prospects for the powdered baby milk segment, suggesting weaker expected returns from this line. This extraordinary loss has been incorporated into the company’s consolidated financial results for the 2025 fiscal year and may weigh on reported profitability, signaling strategic and earnings implications for stakeholders monitoring Ezaki Glico’s dairy operations.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen6199.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.
Ezaki Glico reported a 9.1% increase in net sales to ¥361.4 billion for the fiscal year ended December 31, 2025, but operating profit fell 21.0% and profit attributable to owners of parent dropped 37.9%. Earnings per share declined to ¥79.12, reflecting margin pressure despite higher revenues, while the operating profit margin narrowed to 2.4% and ordinary profit to total asset ratio slipped to 3.0%.
Total assets rose to ¥394.1 billion and net assets to ¥278.5 billion, with a still-solid shareholders’ equity ratio of 70.5% and higher net assets per share of ¥4,365.35. Cash flows from operating activities improved sharply to ¥27.3 billion, cash and cash equivalents increased to ¥64.7 billion, and reduced cash outflows from financing activities suggest a stabilizing balance sheet despite weaker profitability, with implications for dividends and future investment capacity.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen6199.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.
Ezaki Glico Co., Ltd. has revised its full-year financial forecast for 2025, citing a reduction in expected net sales and profits due to a chocolate recall and sluggish sales in its ice cream and chilled products sectors. Despite these downward revisions, the company has maintained its dividend forecasts, indicating a commitment to shareholder returns amidst operational challenges.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen5844.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.
Ezaki Glico Co., Ltd. has announced a voluntary recall of 20 chocolate products, including popular items like Pocky Chocolate, due to unintended flavor variations caused by spice contamination during warehouse renovations. While there are no safety concerns, the company is taking steps to prevent future occurrences and is assessing the financial impact of this recall on its fiscal year ending December 2025.
The most recent analyst rating on (JP:2206) stock is a Hold with a Yen5844.00 price target. To see the full list of analyst forecasts on Ezaki Glico Co., Ltd. stock, see the JP:2206 Stock Forecast page.